Paxlovid for Severe COVID-19 Risk
A Study on Paxlovid Once in the Market, to Observe Its Safety and Effectiveness in Patients Who Have a High Chance of Getting Severe COVID-19
Recruiting
Observational Study
COVID-19
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 3,000 (estimated)
- Sponsor
- Pfizer · Industry
Who this trial is looking for
This trial is looking for patients with mild to moderate COVID-19 symptoms who are at high risk of developing severe illness. Participants will receive Paxlovid as part of their usual care and will be followed for 28 days to check for safety and effectiveness.
Are You a Good Fit for This Trial?
You may be able to join if
- I have mild to moderate COVID-19 symptoms
- I am at high risk for severe COVID-19
- I have taken or will take Paxlovid as approved
- I understand the study and have signed consent
You may not be able to join if
- I have a condition that prevents me from taking Paxlovid
- I will take any investigational medicine during the study
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to look at the safety and effectiveness of PAXLOVID in the real world and not in clinical studies. The study observes patients who have a high chance of getting severe COVID-19 in Korea.
This study is seeking participants who are:
* Patients with mild-to-moderate COVID-19 symptoms and at high chance of getting severe COVID-19, including hospitalization or death.
* Pa…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients who received, are currently receiving, or are going to receive PAXLOVID according to locally approved label.
* Patients (or a legally acceptable representative) who are willing to provide written informed consent/assent prior to study enrollment.
Exclusion Criteria:
…
Contacts